Eyebiotech Ltd. doubled the size of its series A round, raising $130 million to advance a pair of assets, with a phase Ib/IIa trial dubbed Amarone underway testing the drug called Restoret in patients with diabetic macular edema and neovascular, or wet, age-related macular degeneration.
Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
The canonical Wnt signaling pathway participates in synapse function and stability, and previous research confirmed its impairment in Alzheimer's disease (AD).
LONDON – Redx Pharma plc is in the process of handing its RXC-006 program over to Astrazeneca plc, after signing a potential $377 million development and commercialization deal for the porcupine inhibitor in the treatment of fibrotic disease.